{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:22:15Z","timestamp":1784373735538,"version":"3.55.0"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone metastasis is one of the predominant causes of cancer lethality. This study demonstrates for the first time how \u03b22-microglobulin (\u03b22-M) supports lethal metastasis in vivo in human prostate, breast, lung, and renal cancer cells. \u03b22-M mediates this process by activating epithelial to mesenchymal transition (EMT) to promote lethal bone and soft tissue metastases in host mice. \u03b22-M interacts with its receptor, hemochromatosis (HFE) protein, to modulate iron responsive pathways in cancer cells. Inhibition of either \u03b22-M or HFE results in reversion of EMT. These results demonstrate the role of \u03b22-M in cancer metastasis and lethality. Thus, \u03b22-M and its downstream signaling pathways are promising prognostic markers of cancer metastases and novel therapeutic targets for cancer therapy. Cancer Res; 71(7); 2600\u201310. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-3382","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T23:57:39Z","timestamp":1300838259000},"page":"2600-2610","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["\u03b22-Microglobulin Induces Epithelial to Mesenchymal Transition and Confers Cancer Lethality and Bone Metastasis in Human Cancer Cells"],"prefix":"10.1158","volume":"71","author":[{"given":"Sajni","family":"Josson","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Nomura","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"},{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Tai","family":"Lin","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chin","family":"Huang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyen E.","family":"Zhau","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Zayzafoon","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Neale","family":"Weizmann","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"},{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Gururajan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland W. K.","family":"Chung","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; 2Molecular Urology and Therapeutics and 3Division of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; and 5Atlanta Veterans Affairs Medical Center, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,3,31]]},"reference":[{"key":"2022061702445624700_bib1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061702445624700_bib2","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1021\/bi00748a001","article-title":"The complete amino acid sequence of beta 2-microglobulin","volume":"12","author":"Cunningham","year":"1973","journal-title":"Biochemistry"},{"key":"2022061702445624700_bib3","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.139.9.3132","article-title":"The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit","volume":"139","author":"Gussow","year":"1987","journal-title":"J Immunol"},{"key":"2022061702445624700_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-3083.1994.tb03341.x","article-title":"The interaction between beta 2-microglobulin (beta 2m) and purified class-I major histocompatibility (MHC) antigen","volume":"39","author":"Pedersen","year":"1994","journal-title":"Scand J Immunol"},{"key":"2022061702445624700_bib5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0092-8674(86)90019-X","article-title":"The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides","volume":"44","author":"Townsend","year":"1986","journal-title":"Cell"},{"key":"2022061702445624700_bib6","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1158\/1078-0432.CCR-08-0793","article-title":"Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells","volume":"14","author":"Huang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061702445624700_bib7","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1158\/0008-5472.CAN-06-1996","article-title":"beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702445624700_bib8","doi-asserted-by":"crossref","first-page":"7947","DOI":"10.1074\/jbc.M109.092759","article-title":"Androgen receptor survival signaling is blocked by anti-{beta}2-microglobulin monoclonal antibody via a mitogen-activated protein kinase\/lipogenic pathway in human prostate cancer cells","volume":"285","author":"Huang","year":"2010","journal-title":"J Biol Chem"},{"key":"2022061702445624700_bib9","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-06-1156","article-title":"Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer","volume":"13","author":"Gross","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061702445624700_bib10","first-page":"781","article-title":"Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action","volume":"55","author":"Rowley","year":"1995","journal-title":"Cancer Res"},{"key":"2022061702445624700_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2006.08.025","article-title":"Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies","volume":"10","author":"Yang","year":"2006","journal-title":"Cancer Cell"},{"key":"2022061702445624700_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0009-8981(77)90346-1","article-title":"Serum beta2-microglobulin in controls and cancer patients","volume":"78","author":"Teasdale","year":"1977","journal-title":"Clin Chim Acta"},{"key":"2022061702445624700_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/00365597709179690","article-title":"Urinary excretion of ten plasma proteins in patients with renal carcinoma","volume":"11","author":"Hemmingsen","year":"1977","journal-title":"Scand J Urol Nephrol"},{"key":"2022061702445624700_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0009-8981(76)90339-9","article-title":"beta 2-microglogulin levels in cancerous and other disease states","volume":"67","author":"Shuster","year":"1976","journal-title":"Clin Chim Acta"},{"key":"2022061702445624700_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/1477-5956-6-19","article-title":"Proteomic profiling of urine for the detection of colon cancer","volume":"6","author":"Ward","year":"2008","journal-title":"Proteome Sci"},{"key":"2022061702445624700_bib16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10529-009-0027-0","article-title":"Beta2-microglobulin as a potential factor for the expansion of mesenchymal stem cells","volume":"31","author":"Zhu","year":"2009","journal-title":"Biotechnol Lett"},{"key":"2022061702445624700_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0006-291X(91)91635-P","article-title":"Immunoreactivity and proliferative actions of beta 2 microglobulin on human bone-derived cells in vitro","volume":"175","author":"Evans","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"2022061702445624700_bib18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/ki.2008.100","article-title":"Beta2-microglobulin stimulates osteoclast formation","volume":"73","author":"Menaa","year":"2008","journal-title":"Kidney Int"},{"key":"2022061702445624700_bib19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1073\/pnas.93.4.1529","article-title":"beta2 knockout mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism","volume":"93","author":"Rothenberg","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702445624700_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bcmd.2004.05.003","article-title":"Molecular analysis of iron overload in beta2-microglobulin-deficient mice","volume":"33","author":"Muckenthaler","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"2022061702445624700_bib21","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1073\/pnas.95.4.1472","article-title":"The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding","volume":"95","author":"Feder","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702445624700_bib22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/pros.20488","article-title":"Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis","volume":"66","author":"Xu","year":"2006","journal-title":"Prostate"},{"key":"2022061702445624700_bib23","first-page":"2577","article-title":"Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer","volume":"54","author":"Thalmann","year":"1994","journal-title":"Cancer Res"},{"key":"2022061702445624700_bib24","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1158\/1078-0432.CCR-06-2060","article-title":"Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis","volume":"12","author":"Nomura","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061702445624700_bib25","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1158\/1078-0432.CCR-05-1010","article-title":"Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma","volume":"11","author":"Inoue","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2022061702445624700_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1006598422203","article-title":"LCC15-MB: a vimentin-positive human breast cancer cell line from a femoral bone metastasis","volume":"17","author":"Thompson","year":"1999","journal-title":"Clin Exp Metastasis"},{"key":"2022061702445624700_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0277-5379(82)90025-6","article-title":"Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status","volume":"18","author":"Bataille","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2022061702445624700_bib28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","article-title":"Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis","volume":"14","author":"Yang","year":"2008","journal-title":"Dev Cell"},{"key":"2022061702445624700_bib29","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1182\/blood.V82.12.3610.3610","article-title":"Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction","volume":"82","author":"Wang","year":"1993","journal-title":"Blood"},{"key":"2022061702445624700_bib30","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1038\/sj.onc.1210316","article-title":"cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis","volume":"26","author":"Wu","year":"2007","journal-title":"Oncogene"},{"key":"2022061702445624700_bib31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00198-005-1934-0","article-title":"Bone mineral density in men with genetic hemochromatosis and HFE gene mutation","volume":"16","author":"Guggenbuhl","year":"2005","journal-title":"Osteoporos Int"},{"key":"2022061702445624700_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3816\/CGC.2006.n.034","article-title":"Stromal-epithelial interaction in prostate cancer progression","volume":"5","author":"Chung","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"2022061702445624700_bib33","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ndt\/16.6.1108","article-title":"Beta(2)-microglobulin and bone cell metabolism","volume":"16","author":"Balint","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2022061702445624700_bib34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2022061702445624700_bib35","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2007-06-094417","article-title":"Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"2022061702445624700_bib36","article-title":"Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells","volume":"9:9.","author":"Zhang","year":"2010","journal-title":"Mol Cancer"},{"key":"2022061702445624700_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10555-010-9225-4","article-title":"Metastasis: cancer cell's escape from oxidative stress","volume":"29","author":"Pani","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"2022061702445624700_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcancer.2008.11.009","article-title":"Regulation of cancer cell metabolism by hypoxia-inducible factor 1","volume":"19","author":"Semenza","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"2022061702445624700_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0092-8674(00)81151-4","article-title":"Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor","volume":"93","author":"Lebron","year":"1998","journal-title":"Cell"},{"key":"2022061702445624700_bib40","first-page":"4317","article-title":"Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer","volume":"21","author":"Giatromanolaki","year":"2001","journal-title":"Anticancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/7\/2600\/2665345\/2600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/7\/2600\/2665345\/2600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T06:40:13Z","timestamp":1712299213000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/71\/7\/2600\/574107\/2-Microglobulin-Induces-Epithelial-to-Mesenchymal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,31]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,3,31]]},"published-print":{"date-parts":[[2011,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-3382","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22390007","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22390001.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22389998.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502796","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22390004.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22390010","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22390001","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22390004","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22390007.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502796.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22389998","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22390010.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,31]]}}}